Jaguar Health Receives $3 Million Payment From Future Pak for Mytesi and Canalevia-CA1 License Deal

Reuters
03/03
Jaguar Health Receives $3 Million Payment From Future Pak for Mytesi and Canalevia-CA1 License Deal

Jaguar Health said it received a $3 million payment from Future Pak after terminating the buy-back provision in their U.S. licensing agreement for Mytesi and Canalevia-CA1. The company said the termination allows Future Pak to continue commercializing Mytesi beyond five years, while Jaguar will continue manufacturing Mytesi and Canalevia-CA1 for Future Pak. Jaguar previously reported receiving $16 million in upfront non-dilutive capital in January 2026 upon entering the agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603030900ACCESSWRNAPR_____1142997) on March 03, 2026, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10